| Document |
Document Title |
|
WO/2017/024015A1 |
4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by...
|
|
WO/2017/020831A1 |
Provided is an organic light-emitting compound shown in a general formula (I) and use thereof in preparation of an organic light-emitting device. The provided organic light-emitting compound is capable of reducing a working voltage of th...
|
|
WO/2017/021981A1 |
The present invention relates to a dosage form comprising an aqueous solution of a vinca alkaloid drug or its pharmaceutically acceptable salt in a flexible infusion container, and a light protective secondary packaging containing the fl...
|
|
WO/2017/019429A1 |
Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
|
|
WO/2017/018153A1 |
The present invention provides a compound represented by general formula (I) (wherein Ra0 represents a hydrogen atom, a hydroxy group, an alkyl group having 1 to 12 carbon atoms, or an alkenyl group having 3 to 12 carbon atoms; Ra1, Ra2,...
|
|
WO/2017/015267A1 |
Compounds of the formulas I and XIII, which are useful as colony stimulating factor-1 receptor inhibitors ("CSF 1R inhibitors").
|
|
WO/2017/010124A1 |
The present invention addresses the problem of providing an organic thin-film laminate with which it is possible to suppress function reduction even when an intermediate layer is formed using a wet method. The organic thin-film laminate ...
|
|
WO/2017/009804A1 |
The present invention provides for compounds of formula (I) wherein X, Y, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases a...
|
|
WO/2017/005583A1 |
The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein L and R1 to R5 are as described herein, as well as processes for their manufacture, pharmaceutical compositions comprising th...
|
|
WO/2017/006968A1 |
The present invention provides: a method for producing a 7H-pyrrolo[2, 3-d]pyrimidine derivative that is useful as a janus kinase (JAK) inhibitor; an intermediate of the 7H-pyrrolo[2, 3-d]pyrimidine derivative; and a method for producing...
|
|
WO/2017/000779A1 |
Provided is an organic compound as shown by formula (I), which is a high performance material obtained by coupling anthracene and a derivative of anthracene with phenanthroline via a naphthyl. Also provided are an electronic material wit...
|
|
WO/2017/001660A1 |
The present invention relates to the following compounds, wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2017/004025A1 |
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 do...
|
|
WO/2017/004408A1 |
Disclosed are new small molecules having a 4-methylpyrrrolo[l,2-a]pyrimidine- 8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the sma...
|
|
WO/2016/209951A1 |
Macrocyclic benzodiazepine dimers having a structure represented by formula (I) where A and B are independently according to formulae (Ia) or (Ib) ]; and the other variables in formulae (I), (Ia), and (Ib) are as defined in the applicati...
|
|
WO/2016/208595A1 |
The present invention pertains to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the signs set forth in the description), or a salt, a solvate or an N-oxide thereof, or a prodrug of tho...
|
|
WO/2016/203404A1 |
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.
|
|
WO/2016/203401A1 |
The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.
|
|
WO/2016/202800A1 |
New pyrrolotriazinone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositid...
|
|
WO/2016/205113A1 |
A number of new classes of polymers with the potential for electrical conduction are introduced sharing a common theme, having metal atoms in direct contact with each other, bound in one and two-dimensional structures guided by steric, d...
|
|
WO/2016/204135A1 |
The present invention relates to a compound, or a pharmacologically acceptable salt thereof, that has excellent hypoglycemic action. A compound represented by general formula (I) or a pharmacologically acceptable salt thereof. [In the fo...
|
|
WO/2016/198869A1 |
The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7- 6–membered rings and to benzopyrridodiazecines (BPDs) comprising three fused 6-8- 6–membered rings and, in particular, to PDD or BPD dimers linked t...
|
|
WO/2016/197584A1 |
The present invention relates to the field of preparation of natural plant extracts, and particularly relates to a method of extracting Azadirachtin from neem seeds. The method comprises: first adding peeled neem seeds and sodium rosinat...
|
|
WO/2016/201219A1 |
The disclosure relates to compositions and methods for the treatment of fungal, bacterial, and parasitic infections and inhibition of fungal, bacterial, and parasitic growth. In particular, such compositions include dihydrofolate reducta...
|
|
WO/2016/200339A1 |
A compound of formula I, wherein the compound of formula I has the structure: wherein R1 to R5, Y, L, Z and X1 to X7 have meanings given in the description, said compounds having utility in the treatment of hyperproliferative disease.
|
|
WO/2016/197987A1 |
The present invention provides a heterocyclic compound serving as a Syk inhibitor and/or a Syk-HDAC dual inhibitor. Specifically, the present invention provides a compound represented by formula (I), wherein each group is defined by a de...
|
|
WO/2016/192329A1 |
A benzo[g]phthalazine-containing aromatic heterocyclic compound as represented by formula (I), a preparation method for the compound, and an organic electroluminescent component comprising the compound. The compound as represented by for...
|
|
WO/2016/192346A1 |
Provided is an aromatic heterocyclic derivative having a structure as represented by formula (I). Compared with the prior art, the aromatic heterocyclic derivative provided in the present invention is such that groups Q1, Q2, Ar1, Ar2, A...
|
|
WO/2016/194831A1 |
The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
|
|
WO/2016/191524A1 |
The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compos...
|
|
WO/2016/189304A1 |
The present invention relates to antibacterial drug compounds containing a polycyclic ring system incorporating a macrocyclic ring. The invention also relates to pharmaceutical formulations of antibacterial drug compounds. The invention ...
|
|
WO/2016/184832A1 |
The present invention provides compounds of formula (I) wherein A, X, Y, R1 and R2 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the comp...
|
|
WO/2016/181773A1 |
The present invention provides a π-conjugated compound that increases light-emission efficiency without increasing light-emission wavelength. This π-conjugated compound is a compound having a structure indicated by general formula (1)....
|
|
WO/2016/181772A1 |
The present invention provides a π-conjugated compound that increases light-emission efficiency without increasing light-emission wavelength. This π-conjugated compound is a compound having a structure indicated by general formula (1)....
|
|
WO/2016/181844A1 |
In order to provide a π-conjugated compound that increases light-emission efficiency, this π-conjugated compound has: an absolute value for the difference between the lowest excited singlet energy level and the lowest excited triplet e...
|
|
WO/2016/181846A1 |
In order to provide a novel π-conjugated compound capable of increasing the light-emission efficiency of an organic electroluminescence element, for example, this π-conjugated compound has a structure indicated by general formula (1). ...
|
|
WO/2016/174079A1 |
The invention concerns novel substituted pyrazolo- and triazolo-pyrimidine compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The ...
|
|
WO/2016/169995A1 |
Compounds of formula (I) (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, L1 and G1 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive all...
|
|
WO/2016/171181A1 |
Provided are fused pyrazole derivatives and pharmaceutically acceptable salts thereof that act at high selectivity on dopamine D4 receptors and are useful as agents for the treatment of attention deficit-hyperactivity disorder and the li...
|
|
WO/2016/169911A1 |
A compound according to Formula (I): wherein R1, LA, CyA, RA, R2, R3, and R4 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is inv...
|
|
WO/2016/171142A1 |
The present invention relates to a compound potentially useful for treating or preventing SPT-related disease including congenital disease accompanied by sphingolipid accumulation, including cancer and Niemann-Pick disease.
|
|
WO/2016/165808A1 |
Compounds of the formula (I), in which W, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of ALK1, AL2 and ALK5, and can be employed for the treatment of diseases such as cancer.
|
|
WO/2016/168638A1 |
The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure ar...
|
|
WO/2016/168641A1 |
The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, prodrugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the inven...
|
|
WO/2016/168660A1 |
The present invention is directed to compounds of Formulae I and II which are inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurol...
|
|
WO/2016/162318A1 |
The invention relates to novel compounds of formula (I), wherein R1, R2, R3, and Q and n have the meanings indicated in the description, to the use thereof as acaricides and/or insecticides for controlling animal pests, and to methods an...
|
|
WO/2016/161570A1 |
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein CH, R1, R1a, R1b, R2, R3, and the subscripts m1, m2, p, q, and t are as set...
|
|
WO/2016/154998A1 |
Disclosed are a pyrazolopyrimidine derivative, manufacturing method, pharmaceutical composition, and use thereof. Provided are a pyrazolopyrimidine derivative as represented by formula I, a stereoisomer, a solvate, a pharmaceutically acc...
|
|
WO/2016/157074A1 |
The present invention relates to a pyrazole derivative of formula (I), a 5 pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof, stereoisomer thereof or a deuterium form thereof, wherein, n, Y, Ra, R1, R2, R3, R...
|
|
WO/2016/161282A1 |
The present invention is directed to compounds of Formula I which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
|
